Phase 3 Community-acquired Pneumonia Clinical Trials
7 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–7 of 7 trials
Recruiting
Phase 3
AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia
Community-acquired Pneumonia
University of Manitoba4,000 enrolled64 locationsNCT05848713
Recruiting
Phase 3
Amoxicillin Alone Versus Amoxicillin/Clavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, and Hospitalized in a Non-intensive Care Unit Ward
Community-acquired Pneumonia
Nantes University Hospital326 enrolled19 locationsNCT06229288
Recruiting
Phase 3
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
Community-acquired Pneumonia
Biotest590 enrolled147 locationsNCT05722938
Recruiting
Phase 3
Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)
Community-acquired Pneumonia
Hellenic Institute for the Study of Sepsis330 enrolled24 locationsNCT06294600
Recruiting
Phase 2Phase 3
Twice Daily Treatment With Amoxicillin for Non-severe Community Acquired Pneumonia.
Community-acquired Pneumonia
St. Justine's Hospital1,370 enrolled1 locationNCT03031210
Recruiting
Phase 3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Community-acquired Pneumonia, Influenza, COVID-19
UMC Utrecht20,000 enrolled408 locationsNCT02735707
Recruiting
Phase 3
A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Three-Arm Study to Evaluate the Safety and Efficacy of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) Administration in Subjects with Severe Community-Acquired Pneumonia
Severe Community-Acquired Pneumonia
Novartis Pharmaceuticals Corporation2,100 enrolled16 locationsACTRN12607000460404